What It Is
5-Amino-1MQ is frequently marketed and searched for as a "peptide," but that label is chemically inaccurate. The compound, formally 5-amino-1-methylquinolinium, is a small synthetic molecule rather than a chain of amino acids, and it is listed as such in chemical databases like PubChem and the FDA's Global Substance Registration System.[1] It is studied as a selective, membrane-permeable inhibitor of an enzyme called nicotinamide N-methyltransferase, or NNMT.
Because online body-composition and longevity content often lumps metabolic research compounds together with true peptides, 5-Amino-1MQ shows up in peptide-therapy searches despite its distinct chemical class. Common naming variants include 5-Amino-1MQ, 5-amino-1-methylquinolinium, 5-AMQ, and 5A-1MQ, all referring to the same research molecule.
How It Works
NNMT is an enzyme that transfers a methyl group from S-adenosylmethionine (SAM) to nicotinamide (a form of vitamin B3). This reaction sits at a crossroads of NAD-related energy metabolism and methylation biology, and NNMT activity varies by tissue, playing different roles in liver, fat, muscle, and cancer cells.[2]
By blocking NNMT, 5-Amino-1MQ is hypothesized to shift this balance in ways that affect fat cell metabolism. In cultured fat cells, NNMT inhibitors lowered 1-methylnicotinamide while raising NAD+ and SAM, and suppressed the pathway that builds new fat. A separate discovery using genetic knockdown of NNMT, rather than the drug itself, found that removing NNMT protected mice from diet-induced obesity, lending plausibility to the target. None of this proves that inhibiting NNMT produces clinical benefit in people.
What the Research Shows
The evidence for 5-Amino-1MQ is preclinical. In diet-induced-obese mice, the compound reduced body weight, white-fat mass, adipocyte size, and cholesterol without reducing food intake.[2] A follow-up mouse study combining an NNMT inhibitor with a reduced-calorie diet reported improvements in body composition and liver fat compared with diet change alone.[5] Separate mouse work examined aged muscle and exercise responses, while a pharmacokinetic study characterized the compound in rats rather than people.[6][13]
No registered or completed human efficacy study of 5-Amino-1MQ was identified in the sources reviewed through August 10, 2026.[20] Claims about human fat loss, longevity, mitochondrial health, or disease treatment therefore remain extrapolations from animal and cell experiments.
Safety & Side Effects
Human safety data for 5-Amino-1MQ were not identified. A 2018 mouse experiment reported no observable adverse effects during its short treatment period, but that result cannot establish human safety.[2] Long-term toxicity, reproductive safety, organ impairment, medicine interactions, and the consequences of inhibiting an enzyme with tissue-dependent roles in cancer biology remain unknown.[10]
An absence of adverse-event reports is not reassuring when there is no systematic human exposure program. Products sold as compounded or research-grade 5-Amino-1MQ add identity, concentration, impurity, and manufacturing risks; FDA does not review compounded drugs for safety, effectiveness, or quality before marketing.[15]
Regulatory Status
5-Amino-1MQ is not an FDA-approved drug and has no approved label, indication, or human dose. PubChem and FDA's Global Substance Registration System contain chemical identity records for 5-amino-1-methylquinolinium, but FDA explicitly states that assignment of a UNII or inclusion in GSRS does not imply regulatory review or approval.[1][9]
Section 503A places conditions on the use of bulk substances in compounding; an online product labeled "compounded" or "research use" is not thereby an approved medicine or a clinically validated formulation.[17] No standard human regimen should be inferred from the mouse and rat studies.